Implications of CATIE for mental health services researchers

Psychiatric Services

Volumn 59, Issue 5, 2008, Pages 526-529

  Covell, Nancy H ^a,b   Finnerty, Molly T ^c   Essock, Susan M ^d  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Department of Mental Health and Addiction Services   (United States)

^c NEW YORK STATE OFFICE OF MENTAL HEALTH   (United States)

^d NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

BODY WEIGHT; CARDIOVASCULAR RISK; COGNITION; DECISION MAKING; DIABETES MELLITUS; DRUG EFFICACY; HEALTH HAZARD; HEART DISEASE; HUMAN; HYPERTENSION; MENTAL HEALTH SERVICE; METABOLIC DISORDER; PATIENT MONITORING; PREVALENCE; SCHIZOPHRENIA; SHORT SURVEY; SIDE EFFECT; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BIOMEDICAL RESEARCH; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; HEALTH PLANNING GUIDELINES; HEALTH POLICY; HUMANS; MASS SCREENING; MENTAL HEALTH SERVICES; METABOLIC SYNDROME X; RISK FACTORS; SCHIZOPHRENIA;

EID: 50849134861     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.59.5.526     Document Type: Short Survey

References (30)

1. Shern DL, Evans ME: The importance of research in mental health service delivery, in Evidence-Based Mental Health Practice. Edited by Drake RE, Merrens MR, Lynde DW. New York, Norton, 2005
2. Bickman L: The application of program theory to the evaluation of a managed mental health care system. Evaluation and Program Planning 19:111-119, 1996
3. Berman WH, Rosen CS, Hurt SW, et al: Toto, we're not in Kansas anymore: measuring and using outcomes in behavioral health care. Clinical Psychology: Science and Practice 5:115-133, 1998
4. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine 353:1209-1223, 2005
5. Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. American Journal of Psychiatry 163:611-622, 2006
6. Stroup TS, Lieberman JA, McEvoy JP, et al: Effectiveness of olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia after discontinuing perphenazine: a CATIE study. American Journal of Psychiatry 164:415-427, 2007
7. Swartz MS, Wagner HR, Swanson JW, et al: The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. Schizophrenia Research 100:39-52, 2008
8. Essock SM, Covell NH, Davis SM, et al: Effectiveness of switching antipsychotic medications. American Journal of Psychiatry 163:2090-2095, 2006
9. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. American Journal of Psychiatry 163:600-610, 2006
10. Nasrallah HA: The roles of efficacy, safety, and tolerability in antipsychotic effectiveness: practical implications of the CATIE schizophrenia trial. Journal of Clinical Psychiatry 68(suppl 1):5-11, 2007
11. Stroup TS: Heterogeneity of treatment effects in schizophrenia. American Journal of Medicine 120(4 suppl 1):S26-S31, 2007
12. Rosenheck RA, Leslie DL, Sindelar J, et al: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. American Journal of Psychiatry 163:2080-2089, 2006
13. Lieberman JA, Hsiao JK: Interpreting the results of the CATIE study. Psychiatric Services 57:139, 2006
14. Moffic HS: Ethical principles for psychiatric administrators: the challenge of formularies. Psychiatric Quarterly 77:319-327, 2006
15. Noser K, Bickman L: Quality indicators of children's mental health services: do they predict improved client outcome? Journal of Emotional and Behavioral Disorders 8:9-18,26, 2000
16. Nasrallah HA, Meyer JM, Goff DC, et al: Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophrenia Research 86:15-22, 2006
17. McEvoy JP, Meyer JM, Goff DC, et al: Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia Research 80:19-31, 2005
18. Goff DC, Sullivan LM, McEvoy JP, et al: A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophrenia Research 80:45-53, 2005
19. Weissman EM, Zhu CW, Schooler NR, et al: Lipid monitoring in patients with schizophrenia prescribed second-generation antipsychotics. Journal of Clinical Psychiatry 67:1323-1326, 2006
20. Newcomer JW: Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. Journal of Clinical Psychiatry 68(suppl 1):20-27, 2007
21. Meyer JM, Davis VG, Goff DC, et al: Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE schizophrenia trial: prospective data from phase 1. Schizophrenia Research, in press
22. Deegan PE, Drake RE: Shared decision making and medication management in the recovery process. Psychiatric Services 57:636-639, 2006
23. Deegan PE, Drake RE: Shared decision making. Psychiatric Services 58:140, 2007
24. Frank RG, Glied SA: Better But Not Well. Baltimore, Johns Hopkins University Press, 2006
25. Keefe RSE, Bilder RM, Davis SM, et al: Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Archives of General Psychiatry 64:633-647, 2007
26. Swartz MS, Perkins DO, Stroup TS, et al: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. American Journal of Psychiatry 164:428-436, 2007
27. Resnick SG, Rosenheck RA, Canive JM, et al: Employment outcomes in a randomized trail of second-generation antipsychotics and perphenazine in the treatment of individuals with schizophrenia. Journal of Behavioral Health Services and Research, in press
28. Swartz MS, Wagner HR, Swanson JW, et al: Substance use in persons with schizophrenia: baseline prevalence and correlates from the NIMH CATIE study. Journal of Nervous and Mental Disease 194:164-172, 2006
29. Swartz MS, Wagner HR, Swanson JW, et al: Substance use and psychosocial functioning in schizophrenia among new enrollees in the NIMH CATIE study. Psychiatric Services 57:1110-1116, 2006
30. Corrigan PW, Boyle MG: What works for mental health system change: evolution or revolution? Administration and Policy in Mental Health 30:379-395, 2003